Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Stomatologiia (Mosk) ; 80(3): 66-71, 2001.
Article in Russian | MEDLINE | ID: mdl-11548297

ABSTRACT

It is known that the septum of the nose participates in sagittal growth of medial face. Teratogenic deficiency of vitamin K promotes premature ossification of the septum cartilage. It results in hypoplasia of maxillonasal complex, development of characteristic concave profile with the impressed and short nose with half the moon naries, infringement of an occlusion. The orthodontic treatment should be carried out from younger children's age. The surgical treatment is directed on elimination of bone-skeletal infringements of an occlusion, reconstruction of normal contours of middle face and lengthening of a nose. In our clinic for the last 13 years 11 patients with Binder's syndrome were examined and operated.


Subject(s)
Dysostoses/pathology , Dysostoses/surgery , Maxilla/abnormalities , Nasal Septum/abnormalities , Dysostoses/complications , Female , Humans , Male , Maxilla/surgery , Nasal Septum/surgery , Oral Surgical Procedures , Syndrome , Vitamin K Deficiency/embryology , Vitamin K Deficiency/etiology
3.
Semin Thromb Hemost ; 21(4): 357-63, 1995.
Article in English | MEDLINE | ID: mdl-8747698

ABSTRACT

The microsomal mixed function oxidase system metabolizes xenobiotics (Phase I) to products that, if not activated and conjugated for excretion (Phase II), are capable of forming conjugates with cellular macromolecules, including DNA, resulting in toxic, mutagenic, or carcinogenic events. Benzo(a)pyrene (BP), a polycyclic aromatic hydrocarbon, is a model carcinogen for this system. Vitamin K1 (phylloquinone) is a regulator of BP metabolism. These studies demonstrate that K1 is capable of increasing Phase I metabolism and decreasing glutathione transferase activity (Phase II) in chick embryo liver; that deprivation of K1 reduces BP/DNA adducts in mouse liver and reduces tumor formation in mice given intraperitoneal BP; and that K1 supplementation increases BP induced tumor formation in mice. However, epidemiologic studies indicate that children of mothers who smoke during pregnancy may not be at increased risk of cancer. It is known that the placentas from these pregnancies exhibit markedly increased levels of arylhydrocarbon hydroxylase induced by the polycyclic aromatic hydrocarbons in tobacco smoke, but there is no corresponding increase in this enzyme activity in the fetus in such pregnancies. We suggest that the low vitamin K level is a secondary protective mechanism for xenobiotics, such as BP, that may escape the primary placental screen. The recently described role of vitamin K-dependent Gla protein as ligands for receptor tyrosine kinases, also establishes K as a link in cell growth and transformation. It is proposed that the small total body pool of K1 in the adult, which is sufficient only to meet continuing needs, and the even smaller pool in the fetus are protective. This protective effect of low K1 levels is particularly important in the presence of the high mitotic rates and rapid cell turnover in the avian embryo and mammalian fetus.


Subject(s)
Cocarcinogenesis , Fetal Diseases/physiopathology , Fetus/metabolism , Infant, Newborn/metabolism , Prenatal Exposure Delayed Effects , Vitamin K 1/physiology , Vitamin K Deficiency/physiopathology , Xenobiotics/pharmacokinetics , 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide/metabolism , Adult , Animals , Biotransformation , Carcinogens/pharmacokinetics , Chick Embryo , DNA Adducts/metabolism , Female , Humans , Liver/embryology , Maternal Exposure , Maternal-Fetal Exchange , Mice , Mice, Inbred ICR , Microsomes, Liver/enzymology , Mixed Function Oxygenases/metabolism , Neoplasms/chemically induced , Neoplasms/epidemiology , Neoplasms, Experimental/chemically induced , Placenta/enzymology , Pregnancy , Smoking/adverse effects , Vitamin K/administration & dosage , Vitamin K/adverse effects , Vitamin K 1/toxicity , Vitamin K Deficiency/drug therapy , Vitamin K Deficiency/embryology , Warfarin/pharmacology , Xenobiotics/toxicity
4.
Semin Thromb Hemost ; 21(4): 364-70, 1995.
Article in English | MEDLINE | ID: mdl-8747699

ABSTRACT

Coumarin derivatives and anticonvulsants administered during pregnancy enter the fetal circulation, interfering with the action of vitamin K. Vitamin K plays a crucial part in the gamma-carboxylation of glutamic acid residues of the vitamin K-dependent coagulation factors prothrombin, FVII, FIX, and FX. Other vitamin K-dependent proteins in the coagulation cascade are protein C and protein S. Vitamin K-dependent bone proteins are osteocalcin and gamma-carboxyglutamate matrix protein. Administration of coumarol derivatives results in under carboxylation of the vitamin K-dependent proteins. Anticoagulation therapy with warfarin is followed by an increased risk of embryopathy, which has been shown to be greatest between gestational weeks 6 and 12. Administration of warfarin is also followed by an increased risk both of fetal intraventricular hemorrhage, and of cerebral microbleedings, which may result in microencephaly and mental retardation. Treatment with coumarol derivatives should therefore be avoided during pregnancy, even in pregnant women with artificial heart valves, and replaced by heparin. Hemorrhage in the newborn related to the use of anticonvulsant drugs during pregnancy occurs very early within the first 24 hours, probably due to increased degradation of vitamin K. Transplacental administration of vitamin K has been shown to prevent neonatal hemorrhage induced by maternal anticonvulsant therapy. Prophylactic administration of vitamin K, especially by intramuscular injection, has been reported to be associated with an increased risk of childhood cancer. However, subsequent extensive studies have yielded no evidence of any relationship between prophylactic vitamin K administration and the occurrence of childhood cancer.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anticoagulants/adverse effects , Anticonvulsants/adverse effects , Coumarins/adverse effects , Fetal Diseases/chemically induced , Pregnancy Complications/drug therapy , Prenatal Exposure Delayed Effects , Vitamin K Deficiency/chemically induced , Vitamin K/physiology , Anticoagulants/pharmacokinetics , Anticonvulsants/pharmacokinetics , Blood Coagulation Factors/metabolism , Child , Cohort Studies , Coumarins/pharmacokinetics , Epilepsy/drug therapy , Female , Hemorrhage/chemically induced , Humans , Infant, Newborn , Maternal-Fetal Exchange , Neoplasms/chemically induced , Neoplasms/epidemiology , Pregnancy , Protein Processing, Post-Translational , Sweden/epidemiology , Thrombosis/drug therapy , United Kingdom/epidemiology , Vitamin K/adverse effects , Vitamin K/therapeutic use , Vitamin K Deficiency/embryology , Vitamin K Deficiency/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...